San Diego-based Cytori Therapeutics (Nasdaq: CYTX) appointed Steven Kesten, M.D., as executive vice president and chief medical officer. In this role, Kesten will lead global clinical development operations and Cytori’s medical affairs activities.
Kesten served as vice president and chief medical officer at Uptake Medical, where he oversaw the completion of the Vapor trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor.
He served for more than 10 years at Boehringer Ingelheim, most recently as the vice president in medicine for marketed products for respiratory disease. During his tenure, Kesten was responsible for the development and execution of large-scale clinical trials and took the medical lead in the global registration, branding and reimbursement of the drug Spiriva, a $3 billion worldwide product for chronic obstructive pulmonary disease. Kesten lived in Germany for three years and is experienced in European regulatory affairs and reimbursement strategies.
In addition, Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke’s Medical Center in Chicago.
He received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.